| 1. |
Page, I. H. and Helmer, O. M. (1939) A crystalline pressor substance, angio-tensin, resulting from reaction of renin and renin
activator. Proc. Soc. Clin. Invest.
12, 17.
|
| |
| 2. |
Munoz, M. J., Braun-Menendez, E., Fasciolo, J. D., and Leloir, L. F. (1939) Hypertensin: the substance causing renal hypertension.
Nature
144, 980.
|
| |
| 3. |
Maxwell, M. H., Bleifer, K. H., Franklin, S. S., and Varady, P. D. (1972) Cooperative study of renovascular hypertension:
demographic analysis of the study. JAMA
220, 1195–1204.
|
| |
| 4. |
Working Group on Renovascular Hypertension. Detection, evaluation and treatment of renovascular hypertension. (1987) Arch. Intern. Med.
147, 820–829.
|
| |
| 5. |
Dean, R. H., Tribble, R. W., Hansen, K. J., O’Neil, E. A., Craven, T. E., and Redding, J. F. (1991) Evolution of renal insufficiency
in ischemic nephropathy. Ann. Surg.
213, 446–456.
|
| |
| 6. |
Davies, D. F. and Shock, N. W. (1950) Age changes in glomerular filtration rate, effective renal plasma flow, and tubular
excretory capacity in adult males. J. Clin. Invest.
29, 496.
|
| |
| 7. |
Lindeman, R. D., Tobin, J. D., and Shock, N. W. (1984) Association between blood pressure and the rate of decline in renal
function with age. Kidney Int.
26, 861–868.
|
| |
| 8. |
Levy, S. B., Talner, L. B., Coel, M. N., Holle, R., and Stone, R. A. (1978) Renal vasculature in essential hypertension: racial
differences. Ann. Intern. Med.
88, 12–16.
|
| |
| 9. |
Bell, E. T. (1953) Renal vascular disease in diabetes mellitus. Diabetes
2, 376.
|
| |
| 10. |
Gavras, H., Brunner, H. R., Thurston, H., and Laragh, J. H. (1975) Reciprocation of renin dependency with sodium volume dependency
in renal hypertension. Science
188, 1316–1317.
|
| |
| 11. |
Gavras, H., Brunner, H. R., Vaughan, E. D., and Laragh, J. H. (1973) Angio-tensin-sodium interaction in blood pressure maintenance
of renal hypertensive and normotensive rats. Science
180, 1369–1372.
|
| |
| 12. |
Mann, S. J. and Pickering, T. G. (1992) Detection of renovascular hypertension: state of the art, 1992. Ann. Intern. Med.
117, 845–853.
|
| |
| 13. |
Myers, B. D., Deen, W. M., and Brenner, B. M. (1975) Effects of norepinephrine and angiotensin II on the determinants of glomerular
ultrafiltration and proximal fluid reabsorption in the rat. Circ. Res.
37, 101–110.
|
| |
| 14. |
Mann, S. J., Pickering, T. G., Sos, T. A., Uzzo, R. G., Sarkar, S., Friend, K., et al. (1991) Captopril renography in the
diagnosis of renal artery stenosis: accuracy and limitations. Am. J. Med.
90, 30–40.
<Occurrence Type="DOI"><Handle>10.1016/0002-9343(91)90503-P</Handle></Occurrence>
|
| |
| 15. |
Tullis, M. J., Zierler, R. E., Caps, M. T., Bergelin, R. O., Cantwell-Gab, K., and Strandness, D. E.,Jr. (1998) Clinical evidence
of contralateral renal parenchymal injury in patients with unilateral atherosclerotic renal artery stenosis. Ann. Vasc. Surg.
12, 122–127.
|
| |
| 16. |
Castleman, B. and Smithwick, R. H. (1943) The relation of vascular disease to the hypertensive state based on a study of renal
biopsies from one hundred hypertensive patients. JAMA
121, 1256.
|
| |
| 17. |
Brenner, B. M., Meyer, T. W., and Hostetter, T. H. (1982) Dietary protein intake and the progressive nature of kidney disease:
the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal
ablation, and intrinsic renal disease. New Engl. J. Med.
307, 652–659.
|
| |
| 18. |
Hollenberg, N. K., Adams, D. F., Solomon, H., Chenitz, W. R., Burger, B. M., Abrams, H. L., et al. (1975) Renal vascular tone
in essential and secondary hypertension: hemodynamic and angiographic responses to vasodilators. Medicine
54, 29–4.
|
| |
| 19. |
Lawton, W. J. (1982) The short-term course of renal function in malignant hypertensives with renal insufficiency. Clin. Nephrol.
17, 277–283.
|
| |
| 20. |
Textor, S. C., Novick, A. C., Tarazi, R. C., Klimas, V., Vidt, D. G., and Pohl, M. (1985) Critical perfusion pressure for
renal function in patients with bilateral atherosclerotic renal vascular disease. Ann. Intern. Med.
102, 308–314.
|
| |
| 21. |
Tuttle, K. R., Chouinard, R. F., Webber, J. T., Dahlstrom, L. R., Short, R. A., Henneberry, K. J., et al. (1998) Treatment
of atherosclerotic ostial renal artery stenosis with the intravascular stent. Am. J. Kidney Dis.
32, 611–622.
|
| |
| 22. |
Ots, M., Mackenzie, H. S., Troy, J. L., Rennke, H. G., and Brenner, B. M. (1998) Effects of combination therapy with enalapril
and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J. Am. Soc. Nephrol.
9, 224–230.
|
| |
| 23. |
Goyal, R. K., Satia, M. C., Bangaru, R. A., and Gandhi, T. P. (1998) Effect of long-term treatment with enalapril in streptozotocin
diabetic and DOCA hypertensive rats. J. Cardiovasc. Pharmacol.
32, 317–322.
|
| |
| 24. |
Nakamura, T., Obata, J., Kimura, H., Ohno, S., Yoshida, Y., Kawachi, H., et al. (1999) Blocking angiotensin II ameliorates
proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int.
55, 877–889.
|
| |
| 25. |
Wolf, G., Ziyadeh, F. N., Zahner, G., and Stahl, R. A. (1996) Angiotensin II is mitogenic for cultured rat glomerular endothelial
cells. Hypertension
27, 897–905.
|
| |
| 26. |
Weiss, R. H. and Ramirez, A. (1998) TGF-beta-and angiotensin-II-induced mesangial matrix protein secretion is mediated by
protein kinase C. Nephrol. Dialysis Transplant.
13, 2804–2813.
|
| |
| 27. |
Ruiz-Ortega, M. and Egido, J. (1997) Angiotensin II modulates cell growth-related events and synthesis of matrix proteins
in renal interstitial fibroblasts. Kidney Int.
52, 1497–510.
|
| |
| 28. |
Hanada, M., Saito, E., Kambe, T., Hagiwara, Y., and Kubo, T. (1999) Evidence for the involvement of platelet-derived growth
factor in the angiotensin II-induced growth of rat vascular smooth muscle cells. Biol. Pharm. Bull.
22, 137–141.
|
| |
| 29. |
Ruiz-Ortega, M., Bustos, C., Hernandez-Presa, M. A., Lorenzo, O., Plaza, J. J., and Egido, J. (1998) Angiotensin II participates
in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte
chemoattractant protein-1 synthesis. J. Immunol.
161, 430–439.
|
| |
| 30. |
Gruden, G., Thomas, S., Burt, D., Zhou, W., Chusney, G., Gnudi, L., et al. (1999) Interaction of angiotensin II and mechanical
stretch on vascular endothelial growth factor production by human mesangial cells. J. Am. Soc. Nephrol.
10, 730–737.
|
| |
| 31. |
Wilson, H. M., Haites, N. E., and Booth, N. A. (1997) Effect of angiotensin II on plasminogen activator inhibitor-1 production
by cultured human mesangial cells. Nephron
77, 197–204.
|
| |
| 32. |
Hamaguchi, A., Kim, S., Yano, M., Yamanaka, S., and Iwao, H. (1998) Activation of glomerular mitogen-activated protein kinases
in angiotensin II-mediated hypertension. J. Am. Soc. Nephrol.
9, 372–380.
|
| |
| 33. |
Ravid, M., Lang, R., Rachmani, R., and Lishner, M. (1996) Long-term renoprotective effect of angiotensin-converting enzyme
inhibition in noninsulin-dependent diabetes mellitus: a 7-year follow-up study. Arch. Intern. Med.
156, 286–289.
|
| |
| 34. |
UK Prospective Diabetes Study Group. (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular
complication in type 2 diabetes: UKPDS 39. Brit. Med. J.
7160, 713–720.
|
| |
| 35. |
Ruggenenti, P., Perna, A., Gherardi, G., Gaspari, F., Benini, R., and Remuzzi, G. [on behalf of Gruppo Italiano di Studi Epidemiologici
in Nefrologia (GISEN)]. (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril:
REIN follow-up trial. Lancet
352, 1252–1256.
<Occurrence Type="DOI"><Handle>10.1016/S0140-6736(98)04433-X</Handle></Occurrence>
|
| |
| 36. |
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., et al. (1999) Renoprotective properties of
ACE-inhibition in non-diabetic nephro-pathies with non-nephrotic proteinuria. Lancet
354, 359–364.
<Occurrence Type="DOI"><Handle>10.1016/S0140-6736(98)10363-X</Handle></Occurrence>
|
| |
| 37. |
The SOLVD Investigators. (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions
and congestive heart failure. New Engl. J. Med.
325, 293–302.
|
| |
| 38. |
Pfeffer, M. A., Braunwald, E., Moye, L. A., Basta, L., Brown, E. J., Jr., Cuddy, T. E., et al., on behalf of the SAVE Investigators.
(1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.
Results of the survival and ventricular enlargement trial. New Engl. J. Med.
327, 669–677.
|
| |
| 39. |
Lees, R. S., Pitt, B., Chan, R. C., Holmvang, G., Dinsmore, R. E., Campbell, L. W., et al. (1996) Baseline clinical and angiographic
data in the Quinapril Ischemic Event (QUIET) Trial. Am. J. Cardiol.
78, 1011–1016.
<Occurrence Type="DOI"><Handle>10.1016/S0002-9149(96)00526-7</Handle></Occurrence>
|
| |
| 40. |
Dahlof, B., Devereux, R. B., Julius, S., Kjeldsen, S. E., Beevers, G., de Faire, U., et al. [for the LIFE study group]. (1998)
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction
in Hypertension. Hypertension
32, 989–997.
|
| |
| 41. |
Mann, J. and Julius, S. (1998) The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events
in hypertension. Rationale and design. Blood Pressure
7, 176–183.
|
| |